Copyright
©The Author(s) 2023.
World J Gastroenterol. Jul 7, 2023; 29(25): 4085-4098
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.4085
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.4085
Figure 1 The sustained virological response rate in the group with mental disorders compared to the control group in intention-to-treat and per protocol analyses and calculated per protocol analysis in the population with mental disorders.
A: The sustained virological response rate (SVR) in the group with mental disorders (n = 942) compared to the control group (n = 13330) in intention-to-treat and per protocol analyses; B: SVR calculated per protocol analysis in the population with mental disorders considering the type of the psychiatric illness in comparison to the control group. All statistical comparisons were performed with Pearson’s chi-square or Fisher’s exact test. ITT: Intention-to-treat; PP: Per protocol.
- Citation: Dybowska D, Zarębska-Michaluk D, Rzymski P, Berak H, Lorenc B, Sitko M, Dybowski M, Mazur W, Tudrujek-Zdunek M, Janocha-Litwin J, Janczewska E, Klapaczyński J, Parfieniuk-Kowerda A, Piekarska A, Sobala-Szczygieł B, Dobrowolska K, Pawłowska M, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders. World J Gastroenterol 2023; 29(25): 4085-4098
- URL: https://www.wjgnet.com/1007-9327/full/v29/i25/4085.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i25.4085